Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Teleflex Incorporated is a global medical technology company that designs, develops, manufactures, and supplies a broad portfolio of single-use medical devices used in critical care and surgical applications. The company operates within the medical devices and healthcare technology industries, focusing on products that support diagnostic, therapeutic, and interventional procedures across hospitals and clinical settings. Teleflex’s portfolio is primarily oriented toward devices that improve patient outcomes while enabling procedural efficiency and safety for clinicians.
The company generates revenue through a diversified set of products used in vascular access, interventional cardiology and radiology, anesthesia, respiratory care, and urology. Teleflex is positioned as a scale-focused, innovation-driven manufacturer with strong regulatory, clinical, and distribution capabilities, particularly in hospital-based care environments. Founded in 1943, Teleflex initially operated as a diversified industrial company before strategically divesting non-medical businesses and completing a transformation into a pure-play medical device company by the early 2010s.
Business Operations
Teleflex reports operations across multiple medical device categories, with revenue primarily generated from the sale of disposable and minimally invasive devices. Its core business lines include Vascular Access, Interventional, Anesthesia, Surgical, Urology, and OEM and Development Services, with many products designed for recurring use in acute-care settings. The company emphasizes proprietary device design, regulatory approvals, and clinician training to sustain demand and pricing stability.
Operations are supported by a global manufacturing and distribution network, including facilities in North America, Europe, Asia, and Latin America. Teleflex controls a range of proprietary technologies and product platforms and distributes them through direct sales forces and third-party distributors depending on region. The company operates through numerous wholly owned subsidiaries and has historically used acquisitions to add differentiated technologies and expand its procedural reach.
Strategic Position & Investments
Teleflex’s strategy centers on driving organic growth through innovation in high-acuity and minimally invasive procedures, complemented by targeted acquisitions that enhance its technology portfolio. Management has prioritized investment in vascular access, interventional cardiology, and surgical technologies where procedural volumes and clinical demand are expanding. The company also focuses on operational efficiency, margin expansion, and disciplined capital allocation.
Notable strategic investments include the acquisition of Z‑Medica, Vascular Solutions, and NeoTract, each of which expanded Teleflex’s presence in emergency medicine, interventional procedures, and urology, respectively. Teleflex continues to invest in emerging device platforms and clinical applications that address unmet needs, particularly in catheter-based interventions and hospital critical-care workflows.
Geographic Footprint
Teleflex is headquartered in Wayne, Pennsylvania, United States, and operates globally with significant revenue derived from both North America and international markets. The company maintains a strong presence in Europe, Asia-Pacific, Latin America, and parts of the Middle East and Africa, supported by regional sales organizations and manufacturing facilities.
International markets represent a substantial portion of Teleflex’s total revenue, reflecting the company’s diversified geographic exposure and ability to navigate multiple regulatory environments. Teleflex’s global footprint enables it to serve multinational healthcare systems and adapt products to local clinical and regulatory requirements.
Leadership & Governance
Teleflex is led by an executive team with deep experience in medical devices, operations, and global healthcare markets. Leadership emphasizes disciplined execution, portfolio optimization, and innovation aligned with clinical needs, supported by governance practices consistent with U.S. public company standards and regulatory oversight.
Key executives include:
- Liam Kelly – Chairman, President, and Chief Executive Officer
- Thomas E. Powell – Executive Vice President and Chief Financial Officer
- John R. Deren – Executive Vice President and Chief Legal Officer
- Julie L. Anderson – Executive Vice President and Chief Human Resources Officer
- Jeffrey A. Black – Executive Vice President and Chief Operating Officer
The leadership team’s strategic vision centers on sustainable growth through focused investment, operational excellence, and continued innovation in high-value medical device categories.